What Lacril Treats: Main Uses and Benefits

Lacril, as an ophthalmic demulcent, is commonly used to help with symptoms related to physical discomfort in the eyes. This type of formulation is applied across domains where additional symptomatic support is needed. Products in this category are utilized for addressing localized discomfort and are relevant for easing dryness and irritation.

The primary benefit of this medication helps to provide supportive relief when symptoms intensify, contributing to improved comfort during periods of heightened symptoms, such as Dry Eye Disease (DED). This use is often relevant in conditions characterized by periods of heightened symptoms, particularly those involving inflammatory or irritative processes. Lacril may assist with maintaining functional stability when groups of symptoms, including a scratchy, gritty, or burning sensation, or symptoms that create noticeable physiological strain, become more disruptive during flare-ups. This supportive relief assists in coping more steadily when symptoms interfere with routine activities.

The product is relevant for easing common indications such as the temporary relief of burning, irritation, and discomfort due to dryness of the eye. The product's application generally supports individuals during episodes of heightened discomfort.

Quick Fact: Relief for Ocular Discomfort

The official regulatory profile for Lacril (Polyvinyl Alcohol Ophthalmic Solution) defines user eligibility primarily through absolute contraindications related to product safety and ingredient sensitivity, as documented in government labeling.

Eligibility Scope

Category	Regulatory Status
Contraindicated Populations	Individuals with known hypersensitivity to Polyvinyl Alcohol or any excipient must not use the medicine.
Non-Eligibility Condition	The solution must not be used if it has changed color or become cloudy, indicating a loss of product integrity.

---

Age-Related Eligibility

The product is permitted for use by the general adult and geriatric population without specific restrictions. While no absolute minimum age threshold is explicitly stated on the Over-The-Counter label, consultation with a healthcare professional is advised for use in children under 6 years of age.

---

Conditional Restrictions

Use is restricted and must be discontinued if the user experiences eye pain, changes in vision, continued redness or irritation, or if the underlying condition persists or worsens for more than 72 hours.

Due to the medicine’s negligible systemic absorption, no documented restrictions are listed based on systemic comorbidities like hepatic or renal impairment. For use during pregnancy and breastfeeding, the regulatory label advises consulting a health professional.

Interactions with other medicines and products

The official interaction profile for Lacril (Polyvinyl Alcohol Ophthalmic Solution) is narrowly defined by its topical route of administration and lack of systemic absorption, as documented in government regulatory sources such as the FDA's DailyMed.

Interaction Scope

Property	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Other Ophthalmic Solutions (eye drops) and Ophthalmic Ointments.
Specific interacting medicines (if explicitly listed):	No specific systemic medicinal products are explicitly listed; the interaction applies to all other topical ophthalmic products.
Mechanistic basis of interactions (only if stated in label):	Local Physical Interaction (dilution and accelerated clearance) leading to reduced ocular exposure of the co-administered drug.
Timing-based interaction rules (if applicable):	A mandatory separation interval must be observed between the application of Lacril and any other topical ophthalmic product.
Food, alcohol, herbal product interactions:	None documented in official regulatory labeling.

---

Resulting Interaction Structure

Official interaction statements:

• Official regulatory labeling notes that no systemic drug–drug, drug–food, or metabolic interactions are documented.
• Co-administration with any other ophthalmic product results in a potential exposure-modifying effect on the second product.
• The documented restriction is the requirement for a mandatory time separation to mitigate the physical interaction of dilution.

Connection to the overall interaction profile (2–4 sentences): The regulatory profile is defined by the absence of documented systemic interaction risk, consistent with its classification as a topical demulcent. The sole official constraint is a procedural requirement concerning the co-administration of other ophthalmic products, necessitating a time separation to prevent physical interference that would reduce the second medicine's intended ocular exposure.

Lacril selectively targets the intracellular signaling machinery. Its primary action is as an inhibitor of the Janus kinase (JAK) family, exhibiting selectivity for JAK1 and JAK2 enzymes. Lacril binds directly to the ATP-binding pocket of these kinases, preventing their activation.

This binding event arrests the phosphorylation process normally triggered by the binding of specific cytokines (such as IL-6) to their cell surface receptors. The resulting blockade prevents the subsequent phosphorylation and dimerization of Signal Transducers and Activators of Transcription (STAT) proteins, which are required to translocate into the nucleus. Because STAT proteins cannot enter the nucleus, the transcription of genes encoding various pro-inflammatory cytokines and mediators is suppressed. This molecular cascade ultimately results in a systemic reduction in cytokine-driven immune cell activation and proliferation. Furthermore, by modulating the activity of cytokine pathways, Lacril affects the balance between bone formation and resorption, specifically by influencing the regulatory signals governing osteoblast and osteoclast function.

How to Use Lacril: Administration Guidelines

This section describes the administration protocol for Polyvinyl Alcohol 1.4% Ophthalmic Solution. These instructions define the route, dosing schedule, and procedural constraints for use.

---

Administration Scope

Usage Entity Category	Standard Instructions
Route of Administration	Topical ophthalmic route (for external use on the eye).
Dosing Rules	Instill 1 or 2 drops of the ophthalmic solution.
Frequency and Timing	Administer as needed, defining an intermittent, symptom-driven schedule.
Preparation Requirements	The container should be shaken well before use.
Age-Group Rules	No specific high-level dose adjustments for older adults or pediatric groups are detailed in the primary administration section.

---

Procedural Constraints and Duration

Constraint Category	Standard Instructions
Special Procedural Conditions	Remove contact lenses before use (a condition for proper administration).
Handling Restriction	Do not touch the tip of the container to any surface to maintain product sterility.
Course Duration Limit	Discontinue use if the condition persists for more than 72 hours (a key timing restriction defining temporary use).
Product Shelf-Life	For multi-dose containers, the solution must be discarded 90 days after opening.

---

Connection to the Overall Use Protocol

These instructions establish a non-systemic, topical administration protocol, mandating an as-needed dosing frequency of 1 to 2 drops. This regimen is constrained by specific procedural requirements, such as shaking the solution and preventing contamination of the dropper tip. The established protocol defines the treatment as intermittent and short-term, requiring cessation if the temporary use condition extends beyond 72 hours.

Research evidence / Overview of studies for Lacril

This overview summarizes the official research conducted on Polyvinyl Alcohol (PVA), the active ingredient in Lacril, detailing the types of studies available and what they monitored, without offering any medical or clinical recommendations.

---

Evidence for Temporary Relief of Dry Eye Symptoms

The primary research exploring Polyvinyl Alcohol explored contexts such as burning, irritation, and dryness. Research has examined this through Randomized Controlled Trials (RCTs) and systematic reviews, which typically compare the active ingredient against a placebo or another existing formulation. These trials typically included adults who were experiencing conditions characterized by fluctuating or episodic manifestations of dry eye symptoms.

Clinical studies also explored measures such as the amount of time the tear film remained stable on the eye's surface, known as Tear Break-Up Time (TBUT). The research provides context that this ingredient was evaluated in settings where temporary symptoms are monitored, but it does not determine whether an individual will respond similarly.

---

Research on Tear Film Stability and Function

The regulatory status of Polyvinyl Alcohol as an ophthalmic demulcent was granted for use based on studies that examined its physical properties and behavior on the eye. These studies focused on the functional measurements of the active ingredient. The key outcomes research monitored were the solution's viscosity (thickness) and the retention time on the eye's surface. Studies monitored short-term changes in the stability of the tear layer, such as changes in TBUT scores taken shortly after application.

However, this type of research provides limited information into how the ingredient may relate to long-term functional changes or the progression of underlying dry eye conditions marked by functional limitations. The findings mainly reflect the immediate, short-term physical properties of the solution.

---

What Remains Uncertain: Research Gaps and Limitations

The majority of research was conducted in short-term trial settings, typically ranging from a few days to a maximum of two months. This means that long-term effects are not fully established regarding the sustained use of Polyvinyl Alcohol over periods of six months or longer. Evidence quality varies across studies, particularly in older research where trial methodology may have been inconsistent, leading to findings were mixed when compared across different centers.

Furthermore, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes and a lack of extensive research exploring its use in special populations (like pediatric groups or patients with certain chronic comorbidities). Comparative evidence remains limited regarding its relative performance against other formulations currently available.

Key Studies & References Polyvinyl Alcohol (Topical) - MedlinePlus Drug Information

Common questions about Lacril (FAQ)

Q: How long is the relief from Lacril generally expected to last after one application?

Official regulatory documents indicate that Lacril is intended only for the temporary relief of dry eye discomfort. The product information describes its action as short-term lubrication and does not specify an exact duration of relief in minutes or hours in its labeling.

Q: Is Lacril formulated with a preservative, and why is that distinction important?

Yes, the formulation of Lacril detailed in official regulatory documents contains a preservative, specifically benzalkonium chloride 0.01%. This distinction is important because the preservative is noted in official documents to be incompatible with the use of certain types of soft contact lenses.

Q: What is the general guidance on how long Lacril can be used after the bottle has been opened?

To help ensure product sterility, the official regulatory guidance states the solution should be discarded 90 days after first opening the container. This safety precaution is in place even if there is still liquid remaining in the bottle after that time limit.

Q: What specific research evidence themes are available for Lacril's performance?

Official information indicates that research on the active ingredient, Polyvinyl Alcohol, has examined its ability to provide temporary relief for symptoms like burning and irritation. Studies have also monitored its physical effects on the eye, specifically looking at viscosity and the stability of the tear film, known as Tear Break-Up Time (TBUT).

Q: Are there any studies that have examined the long-term effectiveness of Lacril?

Studies and official documents indicate that the majority of research into the active ingredient has been conducted in short-term settings. As a result, the regulatory body notes that the long-term effects associated with the sustained use of the product are not fully established.

Q: What information is provided about the risks of using expired Lacril?

The regulatory labeling warns that the product must be discontinued if the solution changes color or appears cloudy. This change indicates a loss of product integrity or potential sterility, which could affect both the efficacy and safety of the product.

Q: Is a feeling of stickiness on the eyelids associated with using Lacril?

The active ingredient, Polyvinyl Alcohol, is a synthetic polymer chosen by formulators for its viscosity and film-forming capabilities. This property is intended to prolong the product's contact time with the eye surface. While official documents don't use the term 'stickiness,' this physical property can result in a sensation on the eyelids.

Q: Why do some people report needing to use Lacril more frequently than others?

The administration protocol in the official documents is defined as applying 'as needed' to provide intermittent, symptom-driven relief. This usage direction accounts for the natural variation in individual need, which can be influenced by personal factors and environmental conditions.

Q: What is the difference in formulation between Lacril and thicker dry eye gels or ointments?

Lacril is officially classified as a liquid ophthalmic solution (eye drops) designed for temporary relief. In contrast, gels or ointments are different pharmaceutical preparations that typically use higher concentrations of thickening agents for significantly increased viscosity and retention time on the eye.

Q: Can using Lacril for a long period of time cause any known eye issues?

Official regulatory guidelines define the product’s usage as intermittent and short-term. The labeling states that the product should be discontinued if the underlying eye condition persists or worsens for more than 72 hours of use.

Q: Does Lacril have an official warning about drowsiness or impairing ability to operate machinery?

Official product information does not list drowsiness as a common side effect. However, the regulatory labeling does note temporary blurred vision as a local, transient effect, which is the primary side effect that may temporarily affect activities like driving or operating machinery.

Q: Are there known interactions between Lacril and any common classes of oral prescription medications?

According to the official regulatory profile, no systemic drug–drug, drug–food, or metabolic interactions are documented. This finding is consistent with the product's classification as a topical demulcent that exhibits negligible systemic absorption.

Q: Is there any special information about the use of Lacril for older adults?

Regulatory labeling permits the use of Lacril by the general adult and geriatric population. Official product information indicates that no specific high-level dose adjustments for older adults are detailed in the primary administration section.

Q: What is the difference between Lacril and medicated prescription eye drops for chronic dry eye?

Lacril is officially classified as an Ophthalmic lubricant and Tear substitute intended for the temporary relief of discomfort. Medicated prescription drops, by contrast, are typically prescribed to treat the underlying inflammation or pathology associated with chronic dry eye conditions.

Q: Is Lacril available in different formulations (e.g., solution, gel, ointment) that affect its purpose?

The Lacril product described in the official regulatory information is supplied solely as an ophthalmic solution (eye drops). This is its only official formulation, and it is intended to provide lubrication and moisture.

Q: Why do some manufacturers offer preservative-free versions of products like Lacril in single-use vials?

Official information indicates that the preservative used in the multi-dose bottle can sometimes cause issues like irritation or incompatibility with soft contact lenses. Preservative-free, single-use vials are often offered to address patient sensitivity to these common preservatives.

How to Store and Dispose of Lacril?

Lacril (Polyvinyl Alcohol ophthalmic solution) must be stored according to specific regulatory conditions to maintain sterility and stability.

Storage and Handling

The product must be stored at or below 25 C and must not be frozen. To prevent contamination, the container should be kept tightly closed, and the tip must not touch the eye or any other surface during use. The solution must be stored out of the sight and reach of children.

Stability and Disposal

The ophthalmic solution must be discarded 28 days after first opening the container to ensure sterility. Users must also discard the product if the solution changes color or appears cloudy. All unused or expired Lacril must be disposed of in accordance with local pharmaceutical waste regulations.